Bristol Myers Squibb Current Ratio 2010-2022 | BMY
Current and historical current ratio for Bristol Myers Squibb (BMY) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Bristol Myers Squibb current ratio for the three months ending December 31, 2022 was 1.25.
| Bristol Myers Squibb Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-12-31 |
$27.27B |
$21.89B |
1.25 |
| 2022-09-30 |
$26.80B |
$18.93B |
1.42 |
| 2022-06-30 |
$30.19B |
$20.92B |
1.44 |
| 2022-03-31 |
$30.12B |
$22.82B |
1.32 |
| 2021-12-31 |
$33.26B |
$21.87B |
1.52 |
| 2021-09-30 |
$31.44B |
$21.46B |
1.47 |
| 2021-06-30 |
$29.16B |
$18.99B |
1.54 |
| 2021-03-31 |
$27.11B |
$17.33B |
1.56 |
| 2020-12-31 |
$30.19B |
$19.08B |
1.58 |
| 2020-09-30 |
$34.28B |
$20.46B |
1.68 |
| 2020-06-30 |
$34.34B |
$23.42B |
1.47 |
| 2020-03-31 |
$31.85B |
$19.23B |
1.66 |
| 2019-12-31 |
$29.35B |
$18.30B |
1.60 |
| 2019-09-30 |
$40.19B |
$10.49B |
3.83 |
| 2019-06-30 |
$37.72B |
$9.71B |
3.88 |
| 2019-03-31 |
$17.09B |
$8.84B |
1.93 |
| 2018-12-31 |
$17.72B |
$10.65B |
1.66 |
| 2018-09-30 |
$14.87B |
$9.69B |
1.53 |
| 2018-06-30 |
$13.87B |
$9.88B |
1.41 |
| 2018-03-31 |
$14.65B |
$9.62B |
1.52 |
| 2017-12-31 |
$14.85B |
$9.56B |
1.55 |
| 2017-09-30 |
$15.05B |
$9.44B |
1.59 |
| 2017-06-30 |
$14.32B |
$9.02B |
1.59 |
| 2017-03-31 |
$13.62B |
$8.49B |
1.60 |
| 2016-12-31 |
$13.70B |
$8.84B |
1.55 |
| 2016-09-30 |
$13.20B |
$9.00B |
1.47 |
| 2016-06-30 |
$12.30B |
$7.89B |
1.56 |
| 2016-03-31 |
$11.22B |
$7.60B |
1.48 |
| 2015-12-31 |
$10.42B |
$8.02B |
1.30 |
| 2015-09-30 |
$12.93B |
$7.16B |
1.81 |
| 2015-06-30 |
$13.06B |
$7.44B |
1.76 |
| 2015-03-31 |
$14.93B |
$7.69B |
1.94 |
| 2014-12-31 |
$14.61B |
$8.46B |
1.73 |
| 2014-09-30 |
$14.18B |
$8.10B |
1.75 |
| 2014-06-30 |
$14.06B |
$7.80B |
1.80 |
| 2014-03-31 |
$14.01B |
$7.52B |
1.86 |
| 2013-12-31 |
$18.92B |
$12.44B |
1.52 |
| 2013-09-30 |
$10.63B |
$8.28B |
1.28 |
| 2013-06-30 |
$10.49B |
$8.35B |
1.26 |
| 2013-03-31 |
$10.08B |
$8.41B |
1.20 |
| 2012-12-31 |
$9.52B |
$8.28B |
1.15 |
| 2012-09-30 |
$9.28B |
$8.20B |
1.13 |
| 2012-06-30 |
$11.01B |
$6.99B |
1.58 |
| 2012-03-31 |
$11.77B |
$7.21B |
1.63 |
| 2011-12-31 |
$15.32B |
$7.78B |
1.97 |
| 2011-09-30 |
$14.87B |
$7.31B |
2.03 |
| 2011-06-30 |
$14.78B |
$7.41B |
1.99 |
| 2011-03-31 |
$13.30B |
$6.76B |
1.97 |
| 2010-12-31 |
$13.27B |
$6.74B |
1.97 |
| 2010-09-30 |
$14.38B |
$6.28B |
2.29 |
| 2010-06-30 |
$12.98B |
$5.91B |
2.20 |
| 2010-03-31 |
$12.53B |
$6.02B |
2.08 |
| 2009-12-31 |
$13.96B |
$6.31B |
2.21 |
| 2009-09-30 |
$13.39B |
$7.39B |
1.81 |
| 2009-06-30 |
$14.57B |
$6.74B |
2.16 |
| 2009-03-31 |
$15.38B |
$6.63B |
2.32 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$142.352B |
$46.159B |
|
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
|
